MedTrace Logo

Alpha-synuclein Level in Saliva to Differentiate Between Idiopathic Parkinson Disease and Iatrogenic Parkinsonian Syndrome

NCT03156647 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2021-07-29

No results posted yet for this study

Summary

The aim of this study is to determine whether a significant reduction in the total level of alpha-synuclein and significant increase in the oligomeric form of alpha-synuclein and therefore the ratio oligomeric:total alpha-synuclein occurs in patients with Parkinson disease compared to patients with drug-induced parkinsonian syndrome.

Conditions

  • Parkinson Disease
  • Parkinsonian Disorders

Interventions

DIAGNOSTIC_TEST

Level of alpha-synuclein

Test of levels of total and ratio total:oligomeric in saliva

Sponsors & Collaborators

  • Centre Hospitalier Universitaire de Nīmes

    lead OTHER

Principal Investigators

  • Giovanni Castelnovo, MD · CHU Nimes

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2020-07-16
Completion
2020-07-16

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03156647 on ClinicalTrials.gov